William Sargeant
Adult Medicine · Montgomery, ALNPI 1235159435
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 365 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,309 and has fallen 76.7% since, to $305 in 2025.
Across 365 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Amarin Pharma, Inc.$608
- Novo Nordisk$520
- Amgen$434
- Astellas Pharma US Inc$377
- AstraZeneca$336
- plus $2K from 26 others
Across 989 payments — averaging $1045.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$1M
- Boehringer Ingelheim$19K
- GSK$12K
What the payments were for
- Food & beverage$6,05898%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 82 | $1,474 |
| Amarin Pharma, Inc. | 37 | $608 |
| Novo Nordisk | 31 | $520 |
| Amgen(2 entities) | 26 | $434 |
| Astellas Pharma US Inc | 20 | $377 |
| AstraZeneca | 19 | $336 |
| Pfizer | 19 | $292 |
| AbbVie(2 entities) | 14 | $265 |
| Bayer | 15 | $263 |
| Johnson & Johnson(2 entities) | 18 | $240 |
| Lilly USA, LLC | 19 | $237 |
| Boehringer Ingelheim | 10 | $162 |
| Sumitomo Pharma America, Inc. | 8 | $142 |
| Sanofi-aventis U.S. LLC | 7 | $104 |
| Novartis | 6 | $81 |
| Ardelyx, Inc. | 3 | $80 |
| Sunovion Pharmaceuticals Inc. | 5 | $68 |
| Phathom Pharmaceuticals, Inc. | 2 | $67 |
| Exact Sciences | 4 | $66 |
| Kowa Pharmaceuticals America, Inc. | 5 | $64 |
| Bioventus LLC | 2 | $35 |
| Dexcom, Inc. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Mylan Specialty L.p. | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Abbott | 1 | $20 |
| Merck | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$121
How this compares
$6,158 in reported general payments places this provider in the 80th percentile of 26 adult medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 236 | $268,783 |
| MounjaroTirzepatide | 205 | $226,822 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 248 | $193,244 |
| JardianceEmpagliflozin | 104 | $139,939 |
| LinzessLinaclotide | 124 | $125,705 |
| EntrestoSacubitril/Valsartan | 108 | $121,482 |
| EliquisApixaban | 108 | $118,342 |
| JanuviaSitagliptin Phosphate | 103 | $100,913 |
| GemtesaVibegron | 108 | $91,720 |
| TrulicityDulaglutide | 89 | $88,376 |
| FarxigaDapagliflozin Propanediol | 56 | $83,189 |
| XareltoRivaroxaban | 70 | $81,525 |
| RybelsusSemaglutide | 36 | $62,778 |
| VascepaIcosapent Ethyl | 109 | $57,620 |
| MyrbetriqMirabegron | 76 | $57,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $520 | $331,562272 claims |
| Lilly USA, LLCMounjaro, Trulicity | $237 | $315,198294 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,474 | $210,017279 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $162 | $146,446116 claims |
| AbbVieLinzess | $265 | $125,705124 claims |
| NovartisEntresto | $81 | $121,482108 claims |
| PfizerEliquis | $292 | $118,342108 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $336 | $107,26888 claims |
| MerckJanuvia, Janumet Xr | $17 | $106,693114 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $142 | $91,720108 claims |
| Johnson & JohnsonXarelto | $240 | $81,52570 claims |
| Astellas Pharma US IncMyrbetriq | $377 | $57,54576 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 26 adult medicine providers in Alabama.
Other adult medicine in Montgomery
- Cliff RobinsonMontgomery$333
- Eyston HunteMobile$139K
- Delano BenjaminForestdale$10K
- Walter BrandnerBirmingham$9K
- Jeremy LedfordOpelika$9K
- Eric BeckerMobile$7K
- Anthony ChestangBirmingham$5K
- Jeremy AllenPell City$4K
- Adeel BodlaMadison$4K
- Yu-Yong Eugene TaiJasper$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.